The Trial That Sold the Company

In MedTech, the acquisition happens at the readout, not at the signing. ALL-RISE for CathWorks. DISRUPT for Shockwave. POWER PAD 2 for AVS. The trial is not validation. The trial is the trigger. Founders who structure their clinical program around FDA clearance instead of around the acquisition readout are optimizing for the wrong milestone. · Juan Vegarra

On March 29, 2026, Dr. Ajay Kirtane presented the one-year results of the ALL-RISE trial at the American College of Cardiology’s annual scientific session in New Orleans. The results were simultaneously published in the New England Journal of Medicine. The trial enrolled 1,930 patients across 59 sites in North America, Asia, Europe, and the Middle East, and demonstrated that CathWorks FFRangio was non-inferior to invasive wire-based physiology assessment in terms of major adverse cardiac events at one year, with improved resource utilization and reduced procedure time.^[1]

Twenty-two days later, on April 20, 2026, Medtronic completed the acquisition of CathWorks for $585 million.^[2] The deal had been announced in February 2026, but the closing was timed to the trial readout, and the acquisition itself had been in the making since a co-promotion agreement Medtronic and CathWorks signed in 2022.^[3] Four years of commercial partnership, one pivotal trial readout, three weeks between the readout and the close. That is what a trial-triggered acquisition actually looks like.

The pattern is not unique to CathWorks. It is the specific sequence that has defined MedTech M&A across the last five years of premium acquisitions. And it produces a specific implication for how founders should design their clinical evidence portfolio, which almost none of them do.

The MedTech trial as commercial event

In pharma and biotech, the pivotal trial readout is a regulatory event. It exists to satisfy the FDA that the drug is safe and effective. The acquisition, if it happens, comes later and is priced on the regulatory outcome. In MedTech, the pivotal trial readout is a commercial event. The acquirer’s board has typically already pre-approved a transaction pending the readout. The trial is not the regulatory checkpoint. The trial is the trigger that releases the transaction.

This is a structural feature of the MedTech acquirer universe. There are roughly ten strategic acquirers who account for the majority of MedTech deal value. They have deep relationships with the KOL investigators who run pivotal trials. They receive interim data and blinded topline results through those relationships in ways that would be regulated in biotech but are normal in MedTech. By the time the public readout happens, the acquirer has already modeled the transaction and secured board approval pending confirmation. The three weeks between readout and signing is not deal negotiation. It is deal execution on terms that were negotiated months earlier.

The founders who understand this design their pivotal trials to serve two masters at once. The trial has to satisfy FDA for clearance. It also has to produce a data narrative that a strategic acquirer’s corp dev team can build an investment thesis around. Those are related but not identical goals. The trial that clears FDA might not be the trial that triggers a $585 million acquisition. The founders who confuse the two end up cleared but unacquired, which is the worst possible commercial position.

What the CathWorks sequence teaches

The CathWorks-Medtronic timing is the cleanest example. Medtronic and CathWorks signed the co-promotion agreement in 2022. For four years, Medtronic co-marketed the FFRangio system in the United States, Europe, and Japan. During those four years, Medtronic’s sales force learned the technology, its clinical champions built adoption, and Medtronic’s corp dev team gathered the operating data that would eventually anchor the acquisition thesis. In February 2026, Medtronic announced intent to acquire CathWorks for $585 million. In March, the ALL-RISE trial reported at ACC. In April, Medtronic closed.^[3]

The trial was not the reason Medtronic bought CathWorks. The four-year partnership was the reason. The trial was the specific event that allowed Medtronic’s board to approve the transaction at the price offered. Without the trial readout, Medtronic could have continued the co-promotion indefinitely. With the trial readout, Medtronic had the specific data narrative required to justify a premium acquisition to their own board and shareholders.

Founders reading this sequence should notice two things. First, the four-year partnership is the acquirer’s diligence. It is not sales. It is not a distribution deal. It is the specific mechanism through which the acquirer verifies technology, management, and commercial fit before committing to an acquisition. If your relationship with a potential acquirer has not moved into some form of operational partnership, you are not in the acquisition pipeline. You are in the theoretical acquisition pipeline. Second, the trial design that supports the acquisition has to be designed years in advance. A pivotal trial that reports at 12 months requires 18 to 24 months of enrollment plus 12 months of follow-up. If the trial that would trigger your acquisition has not been designed by the time you enter Series B, the acquisition timing that everyone is banking on is not going to happen when the plan says it will.

Shockwave, DISRUPT, and the J&J sequence

The Shockwave acquisition by Johnson & Johnson followed a similar pattern with a longer timeline. Shockwave received its first FDA clearance for peripheral use in September 2016.^[4] Between 2016 and 2024, the company ran the DISRUPT trial family, including DISRUPT II and III in the femoropopliteal artery, DISRUPT BTK for below-the-knee applications, and DISRUPT CAD for coronary use. Shockwave went public in 2019 at $17 per share.^[5]

On April 5, 2024, Johnson & Johnson announced the acquisition of Shockwave for $13.1 billion, or $335 per share.^[6] The transaction closed May 31, 2024. Shockwave became J&J MedTech’s thirteenth priority platform, defined as annual sales of at least $1 billion.^[7] The 20x price movement from $17 IPO to $335 acquisition happened over five years, and every step of that price movement was driven by trial readouts. DISRUPT CAD I in 2019. DISRUPT PAD III in 2020. DISRUPT BTK in 2022. Coronary IVL clearance in 2021. Each event moved the stock, and each event moved the acquisition price the strategic universe was willing to pay.

The Shockwave story is often told as an example of a founder who built a great company. It is that. It is also an example of a founder who designed a trial portfolio explicitly to generate a sequence of readouts that would drive both regulatory clearance and acquisition-relevant evidence. The two goals were coordinated across a multi-year evidence strategy, not treated as sequential.

The pre-clearance acquisition

Stryker’s acquisition of Amplitude Vascular Systems in 2026 shows the pattern in a pre-clearance context. Stryker paid up to $835 million for AVS in April 2026. AVS did not have coronary IVL clearance at the time. What AVS did have was positive pivotal data from POWER PAD 2 presented at VIVA 2025 and an active first-in-human coronary study called POWER CAD I. The acquisition was priced on the evidence portfolio, not on the regulatory status.

This is the specific structural insight. Strategic acquirers do not require FDA clearance to acquire. They require evidence sufficient to underwrite the value creation thesis. If the clinical evidence portfolio is strong enough, the acquisition can precede clearance. If the clinical evidence portfolio is thin, even clearance may not be sufficient to trigger acquisition. The evidence portfolio, not the FDA calendar, is what determines when the acquisition window opens.

Founders who plan around the FDA calendar are planning around the wrong milestone. FDA clearance is necessary for commercial launch. It is not sufficient for premium acquisition. What is sufficient is a pivotal trial or trial family that produces the specific data a strategic acquirer’s corp dev team can use to build an internal investment case. Those two goals overlap. They are not identical.

What the sequence looks like from the acquirer’s seat

From the acquirer’s corp dev seat, the sequence looks like this. The acquirer identifies a category with strategic priority. The acquirer identifies the two or three companies with credible technology in that category. The acquirer initiates partnership discussions with the strongest of them, sometimes formalized as co-promotion or distribution agreements. The partnership provides four to six years of operational visibility. During that period, the acquirer’s corp dev team runs a parallel evaluation of the technology, management, and integration path. By the time the pivotal readout approaches, the acquirer has typically pre-committed internally to a transaction pending confirmation. The readout confirms or refutes the pre-commitment. The transaction closes within weeks of the confirmation.

From the target company’s seat, this sequence looks completely different. The target sees a partnership discussion, a partnership agreement, several years of commercial engagement, and then eventually an acquisition offer. The target rarely sees the internal corp dev machinery that has been operating alongside the partnership. What looks like sales engagement is actually diligence. What looks like a distribution deal is actually a pre-acquisition evaluation. Founders who understand this design their partnership behavior differently than founders who treat the partnership as sales.

What founders should actually plan for

Three specific things follow from this pattern. First, the trial that will trigger the acquisition needs to be designed at least three years before the acquisition is desired, because the enrollment and follow-up periods do not compress. Second, the partnership relationships that provide the acquirer’s diligence pathway need to be initiated at least three years before the acquisition is desired, because verification cannot be compressed either. Third, the evidence portfolio needs to serve two masters simultaneously, and the trial designs that serve one master well often serve the other master poorly.

The founder who is running toward FDA clearance without a parallel evidence strategy that maps to strategic acquirer requirements is building a company that will clear but not sell at premium. That is a specific commercial position, and it is not the position most founders think they are building.

The trial is the trigger. The trigger has to be designed. And the design decisions get made years before anyone in the room is thinking about the acquisition.

Juan Vegarra is the author of An Outsider’s Playbook (2026). He is CRO and acting CFO at a pre-commercial medical device company. More essays · Free toolkits · Advisory · Write me